Truist Financial Has Lowered Expectations for UnitedHealth Group (NYSE:UNH) Stock Price

Key Points

• Truist cut its price target on UnitedHealth from $410 to $370 but kept a "buy" rating, implying roughly a 28.65% upside from the current share price.
• Other analysts have also trimmed targets recently (JPMorgan, UBS, Leerink, Deutsche Bank), leaving a consensus price target of about $375.46 and an overall rating of "Moderate Buy."
• UNH traded near $287.61—below its 50- and 200-day moving averages—after reporting Q4 EPS of $2.11 (slightly above estimates) and revenue of $113.22B (just below estimates); institutional investors hold roughly 87.9% of the stock.

UnitedHealth Group (NYSE:UNH - Get Free Report) had its price objective lowered by research analysts at Truist Financial from $410.00 to $370.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the healthcare conglomerate's stock. Truist Financial's price target points to a potential upside of 28.65% from the company's current price.

UNH has been the topic of several other research reports. TD Cowen raised their price objective on shares of UnitedHealth Group from $335.00 to $338.00 and gave the company a "hold" rating in a research report on Thursday, October 30th. Deutsche Bank Aktiengesellschaft downgraded UnitedHealth Group from a "buy" rating to a "hold" rating and set a $333.00 target price on the stock. in a report on Wednesday, October 29th. JPMorgan Chase & Co. lowered their price target on UnitedHealth Group from $425.00 to $389.00 and set an "overweight" rating for the company in a research report on Monday. UBS Group cut their price target on UnitedHealth Group from $430.00 to $410.00 and set a "buy" rating for the company in a report on Wednesday, January 28th. Finally, Leerink Partners reduced their target price on shares of UnitedHealth Group from $410.00 to $345.00 and set an "outperform" rating on the stock in a research report on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, UnitedHealth Group has an average rating of "Moderate Buy" and a consensus price target of $375.46.

UnitedHealth Group Stock Performance

UNH traded up $0.68 during midday trading on Monday, hitting $287.61. 1,114,321 shares of the company traded hands, compared to its average volume of 11,087,918. The company has a quick ratio of 0.82, a current ratio of 0.79 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $260.53 billion, a PE ratio of 21.83, a price-to-earnings-growth ratio of 1.32 and a beta of 0.41. The company's 50-day moving average is $330.74 and its 200 day moving average is $323.73. UnitedHealth Group has a 52 week low of $234.60 and a 52 week high of $606.36.

UnitedHealth Group (NYSE:UNH - Get Free Report) last issued its earnings results on Tuesday, January 27th. The healthcare conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.09 by $0.02. The company had revenue of $113.22 billion during the quarter, compared to analyst estimates of $113.38 billion. UnitedHealth Group had a return on equity of 14.79% and a net margin of 2.69%.The firm's quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the business posted $6.81 EPS. UnitedHealth Group has set its FY 2026 guidance at 17.750- EPS. On average, research analysts expect that UnitedHealth Group will post 29.54 EPS for the current year.

Hedge Funds Weigh In On UnitedHealth Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. North Capital Inc. grew its holdings in shares of UnitedHealth Group by 16.2% during the 3rd quarter. North Capital Inc. now owns 194 shares of the healthcare conglomerate's stock valued at $67,000 after purchasing an additional 27 shares during the last quarter. Sunflower Bank N.A. increased its stake in shares of UnitedHealth Group by 1.5% in the 3rd quarter. Sunflower Bank N.A. now owns 1,916 shares of the healthcare conglomerate's stock worth $662,000 after acquiring an additional 28 shares in the last quarter. Axis Wealth Partners LLC increased its position in UnitedHealth Group by 1.7% during the third quarter. Axis Wealth Partners LLC now owns 1,631 shares of the healthcare conglomerate's stock valued at $563,000 after acquiring an additional 28 shares during the last quarter. Abound Wealth Management boosted its position in shares of UnitedHealth Group by 13.5% during the third quarter. Abound Wealth Management now owns 244 shares of the healthcare conglomerate's stock worth $84,000 after acquiring an additional 29 shares during the last quarter. Finally, Founders Capital Management LLC boosted its stake in UnitedHealth Group by 3.0% during the fourth quarter. Founders Capital Management LLC now owns 982 shares of the healthcare conglomerate's stock valued at $324,000 after buying an additional 29 shares during the last quarter. 87.86% of the stock is currently owned by institutional investors and hedge funds.

UnitedHealth Group Company Profile

UnitedHealth Group Inc is a diversified health care company headquartered in Minnetonka, Minnesota, that operates two primary business platforms: UnitedHealthcare and Optum. Founded in 1977, the company provides a broad range of health benefits and health care services to individuals, employers, governmental entities and other organizations. Its operations span commercial employer-sponsored plans, individual and Medicare and Medicaid programs, and services for customers and health systems in the United States and selected international markets.

UnitedHealthcare is the company's benefits business, administering health plans and networks, managing provider relationships, and offering coverage products for employers, individuals, and government-sponsored programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.